AbbVie Inc. $ABBV Stock Holdings Boosted by McCarley & Cook Financial Planners

McCarley & Cook Financial Planners raised its stake in shares of AbbVie Inc. (NYSE:ABBV) by 510.7% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 2,394 shares of the company’s stock after purchasing an additional 2,002 shares during the quarter. AbbVie comprises about 0.5% of McCarley & Cook Financial Planners’ investment portfolio, making the stock its 23rd largest position. McCarley & Cook Financial Planners’ holdings in AbbVie were worth $626,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Burk Holdings LLC acquired a new position in AbbVie during the second quarter valued at approximately $30,000. Merkkuri Wealth Advisors LLC bought a new stake in AbbVie in the first quarter valued at approximately $34,000. Marquette Asset Management LLC increased its stake in AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. IMG Wealth Management Inc. raised its holdings in AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after purchasing an additional 153 shares during the period. Finally, Principia Wealth Advisory LLC raised its holdings in AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after purchasing an additional 44 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Lutikizumab met its Phase 3 INTREPID trial objectives. AbbVie reported that the experimental treatment for moderate-to-severe hidradenitis suppurativa achieved its primary HiSCR75 endpoint and eight ranked secondary endpoints, including reduced skin pain and fewer disease flares. The drug was generally well tolerated, with no new safety concerns. AbbVie INTREPID Phase 3 results
• Positive Sentiment: Investors continue to see potential in AbbVie’s broader immunology pipeline. Phase 2a results for a possible Skyrizi successor in Crohn’s disease and a promising eczema candidate could help support growth as AbbVie prepares for future patent expirations. Great News for AbbVie Stock Investors
• Neutral Sentiment: The INTREPID results were positive but commercially ambiguous. Although lutikizumab reduced abscess burden and met prespecified endpoints, the magnitude of benefit reportedly fell short of analyst benchmarks. That raises questions about the drug’s competitive positioning and potential sales opportunity, despite the successful trial. AbbVie skin disease drug Phase 3 results
• Negative Sentiment: Analysts characterized the efficacy as underwhelming. Lutikizumab beat placebo by roughly eight percentage points on its main measure, but the result lagged some efficacy benchmarks. Shares of rival MoonLake rose on expectations that its competing hidradenitis suppurativa therapy may remain better positioned. MoonLake reaction to AbbVie trial data
• Negative Sentiment: AbbVie halted an early-stage liver-cancer combination study. The discontinued Phase 1b trial removes one development program from the oncology pipeline, although its financial impact is likely limited compared with the company’s late-stage immunology portfolio. AbbVie liver cancer trial update

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ABBV. Barclays lifted their price target on shares of AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a research report on Wednesday. Canaccord Genuity Group upped their price objective on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Rothschild & Co Redburn upped their price objective on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Scotiabank raised their price objective on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Finally, Piper Sandler lifted their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $278.07.

AbbVie Stock Performance

NYSE ABBV opened at $284.59 on Friday. The business has a 50 day simple moving average of $265.60 and a 200 day simple moving average of $241.46. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $291.40. The stock has a market cap of $502.80 billion, a price-to-earnings ratio of 80.39, a PEG ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the company posted $2.97 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts predict that AbbVie Inc. will post 13.94 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. AbbVie’s dividend payout ratio is currently 195.48%.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.06% of the stock is currently owned by insiders.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.